Technology Transfer Office
Search

PEP-Therapy

Institut Curie
02/03/2021
Share
PEP-Therapy is a IND-stage medical biotechnology company developing peptides as targeted therapies for severe diseases, with an initial focus on oncology.
PEP-Therapy

PEP-Therapy is a IND-stage medical biotechnology company developing peptides as targeted therapies for severe diseases, with an initial focus on oncology.

PEP-Therapy

 

 

Year of creation: 2014

Line of business: Biotechnology

Institut Curie: Behind the technology and R&D partner

 

TECHNOLOGY

PEP-Therapy has developed a proprietary Cell Penetrating and Interfering Peptides (CP&IP) technology for the development of its therapeutic products. These innovative peptides penetrate cells and then specifically block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.

Two major innovations have been combined in a single bi-functional peptide to target efficiently and accurately key cellular mechanisms involved in pathologies:

  • Optimized Cell Penetrating Peptides (CPP), as a "shuttle" to deliver drugs pharmaceutically active peptides into the cell and also into specific organelles;

  • Short Interfering peptides specifically designed to target relevant protein/protein interactions, thus blocking key mechanisms of diseases, with no effect on other physiological functions of the two proteins.

The company's lead product and first CP&IP-based product, PEP-010, is an anti-cancer agent and is entering Phase Ia/b clinical trial in Q1 2021 in partnership with two leading European cancer hospitals, Institut Curie and Gustave Roussy.

 

APPLICATIONS

Oncology & other severe diseases.

 

More about PEP-Therapy: